Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab
Linda Bouhlel, Jérôme Doyen, Emmanuel Chamorey, Michel Poudenx, Marius Ilie, Jocelyn Gal, Joël Guigay, Jonathan Benzaquen, Charles-Hugo Marquette, Jean-Philippe Berthet, Jérôme Mouroux, Renaud Schiappa, Bernard Padovani, Paul Hofman, Josiane Otto